2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Omics Technologies, Serologic Tests, Bioinformatics, Profiling, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Women’s Health, Biological Processes, Apoptosis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Immunodeficiency, White Blood Cell Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Indolent Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Animal Model
PAPER

2982 The efflux pump MDR1 promotes tumor-specific CD8 T cell persistence and antitumor activity

Lincoln A Brown, MD, Megan Erwin, PhD2, Zachary D Ewell3, Natalie R Favret, PhD4, Melissa M Wolf, PhD5, Claudia N McDavid6, Jessica J Roetman, PhD7, Mary Philip, MD, PhD8
1 Vanderbilt University Medical Center, Nashville, Tennessee, United States
2 Vanderbilt University Medical Center, Nashville, Tennessee, United States
3 Vanderbilt University Medical Center, Nashville, Tennessee, United States
4 Vanderbilt University Medical Center, Nashville, Tennessee, United States
5 Vanderbilt University Medical Center, Nashville, Tennessee, United States
6 Vanderbilt University Medical Center, Nashville, Tennessee, United States
7 Vanderbilt University Medical Center, Nashville, Tennessee, United States
8 Vanderbilt University Medical Center, Nashville, Tennessee, United States, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Multidrug efflux pumps, such as multidrug resistance protein 1 (MDR1; also known as p-glycoprotein or ABCB1), are best known for conferring chemotherapy resistance in cancer cells. However, they are also expressed in normal cells and tissues, including immune cells, where their role remains incompletely understood. We investigated the role of efflux pumps in tumor-specific CD8 T cells (TST), a critical question as efflux inhibitors are currently being explored to enhance tumor chemosensitivity. Moreover, we examined how efflux activity regulates TST responses to cytotoxic chemotherapy.

Here, we used a clinically relevant, genetic liver cancer mouse model and human liver cancer samples to study multidrug efflux dynamics in TST. We previously described how TST differentiate within tumors through early reprogrammable (PD1hiCD39lo) to late imprinted (PD1hiCD39hi) dysfunctional/exhausted states, defined by specific transcription factors and surface markers (Nature 2017, 2019). Interestingly, TST efflux capacity, measured using fluorescent efflux pump substrates, progressively increased as TST differentiated from early to late states in both mouse and human liver cancers. To identify the efflux protein responsible for this marked increase in efflux capacity, we analyzed our published transcriptomic datasets and found that Abcb1a, encoding MDR1, was significantly upregulated during TST differentiation. Selective pharmacologic inhibition confirmed that MDR1 was the dominant transporter mediating efflux activity.

Next, we employed CRISPR/Cas9-mediated gene editing to specifically disrupt Abcb1a/b in TST. MDR1-knockout TST (MDR1KO) showed markedly reduced persistence in tumor-bearing mice as compared to control TST (non-targeting gRNA). MDR1KO accumulated increased mitochondrial and cellular reactive oxygen species, as measured by MitoSOX and CellROX staining, and showed reduced viability. These data suggest that MDR1 regulates oxidative homeostasis and blocks cell death, promoting long-term TST persistence.

We next asked how MDR1 affects TST exposed to cytotoxic chemotherapy. Exposure to doxorubicin, an MDR1 substrate, induced significantly greater cell death in MDR1KO compared to controls. To assess antitumor activity, we cocultured TST in vitro with fluorescently labeled cancer cells and monitored tumor growth over time using live-cell imaging. At baseline, both MDR1KO and control TST were able to kill tumor cells, producing high levels of cytokines and granzyme B. In contrast, when exposed to doxorubicin, tumor control by MDR1KO TST was substantially impaired. Thus, MDR1 becomes critical for T cell-mediated antitumor activity in the presence of cytotoxic chemotherapy.

Together, we identify MDR1 as an important regulator of TST function, limiting oxidative stress and promoting T cell survival and cancer cell killing. Our results suggest that therapeutic inhibition of MDR1 may have unintended detrimental effects on antitumor immunity; however, our studies raise the possibility of enhancing MDR1 expression in T cells to improve cancer immunotherapy.

Lincoln A Brown, MD: No relevant conflicts of interest to declare.